Literature DB >> 1148991

Improved survival of patients with intracranial ependymomas by irradiation: doseselection and field extension.

O M Salazar, P Rubin, D Bassano, V A Marcial.   

Abstract

Intracranial ependymomas, treated with postoperative irradiation, have a 50% 5-year survival. Although this rate is good, the issue remains whether the quantity and qualityof survival can be improved by the proper selection of treatment factors, i.e. field size and dose-time relationship. Factors influencing survival and the effect of doseand field selection are considered in 28 intracranial ependymomas. Nineteen spinal primaries are also presented for comparison. Only 10% of the patients treated with dosesbelow 1350 rets are alive, vs. 56% of the patients treated with higher doses. Only21% of the patients treated with partial brain irradiation survived, vs. 57% of those treated with whole brain irradiation. Although an apparent 5-year survival difference was found for the low-grade (63%) vs. high grade (13%) tumors, high-dose whole brain irradiation had a significant effect only on the survival of thehigh-grade tumors. Local recurrences accounted for the majority of theraputic failures. Ten consecutive patients were treated with elctive craniospinal irradiation and exhibited a 3-year survival of 70%, vs. 35% in those treated conventionally to the brain only. Elective craniospinal irradiation, advocated for the high-grade, particularly infratentorial, ependymomas, has currently yieldedhigher survival, lower recurrences, good tolerance, no complications, and excellent quality of survival. Further documentation of this treatment approach is suggested.

Entities:  

Mesh:

Year:  1975        PMID: 1148991     DOI: 10.1002/1097-0142(197506)35:6<1563::aid-cncr2820350614>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Ependymoma diagnosed in the first year of life in Japan in collaboration with the International Society for Pediatric Neurosurgery.

Authors:  H Kudo; S Oi; N Tamaki; Y Nishida; S Matsumoto
Journal:  Childs Nerv Syst       Date:  1990-11       Impact factor: 1.475

2.  Surgical outcome and prognostic factors of spinal intramedullary ependymomas in adults.

Authors:  Ung Kyu Chang; Woo Jin Choe; Sang Kee Chung; Chun Kee Chung; Hyun Jib Kim
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

3.  Posterior fossa ependymomas in adults.

Authors:  C Davis; L Symon
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

4.  Supratentorial ependymomas in childhood: clinicopathological findings and prognosis.

Authors:  R I Ernestus; O Wilcke; R Schröder
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 5.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

Review 6.  Spinal cord ependymomas in children and adolescents.

Authors:  Martin Benesch; Didier Frappaz; Maura Massimino
Journal:  Childs Nerv Syst       Date:  2012-09-08       Impact factor: 1.475

7.  Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.

Authors:  A T Bergenheim; M Hartman; J Bergh; P A Ridderheim; R Henriksson
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Recurrent pituitary ependymoma: a complex clinical problem.

Authors:  Rosie Belcher; Harvinder S Chahal; Jane Evanson; Farhad Afshar; Silvia Marino; Ashley B Grossman
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

9.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

10.  Tumors of the lateral ventricles.

Authors:  R Delfini; M Acqui; P A Oppido; R Capone; A Santoro; L Ferrante
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.